Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for Geron in a report released on Tuesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings of ($0.08) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Geron's current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron's FY2026 earnings at ($0.13) EPS, FY2027 earnings at $0.05 EPS and FY2028 earnings at $0.35 EPS.
Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $0.88 million for the quarter, compared to analysts' expectations of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The company's quarterly revenue was up 2941.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.09) EPS.
A number of other analysts also recently issued reports on GERN. Wedbush reissued an "outperform" rating and issued a $8.00 price objective on shares of Geron in a report on Thursday, August 8th. Needham & Company LLC restated a "buy" rating and set a $6.00 price objective on shares of Geron in a research note on Friday, August 9th. Scotiabank initiated coverage on Geron in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 target price for the company. Leerink Partners initiated coverage on Geron in a research report on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target on the stock. Finally, StockNews.com raised shares of Geron to a "sell" rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.05.
View Our Latest Research Report on GERN
Geron Stock Performance
Shares of GERN stock traded up $0.02 on Thursday, hitting $4.29. The company's stock had a trading volume of 38,432,521 shares, compared to its average volume of 10,455,006. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a market capitalization of $2.59 billion, a PE ratio of -11.92 and a beta of 0.52. The stock's 50 day moving average is $4.32 and its 200-day moving average is $4.30. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61.
Hedge Funds Weigh In On Geron
Institutional investors have recently added to or reduced their stakes in the stock. Darwin Global Management Ltd. bought a new stake in shares of Geron during the second quarter worth $106,185,000. Renaissance Technologies LLC acquired a new position in Geron in the 2nd quarter worth about $3,315,000. Price T Rowe Associates Inc. MD raised its position in Geron by 999.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company's stock valued at $6,815,000 after purchasing an additional 1,877,184 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Geron during the second quarter valued at about $539,000. Finally, Farallon Capital Management LLC grew its holdings in shares of Geron by 124.6% during the second quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company's stock worth $71,389,000 after purchasing an additional 9,342,000 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Articles
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
